Alnylam Drug Scores Against Rare Nerve Disease
Biotech Alnylam (ALNY) reported positive midstage trial results for its drug candidate patisiran Monday, sending its stock up 20% to a seven-month high on the stock market today. The phase-two trial tested patisiran in familial amyloidotic polyneuropathy (FAP), a rare degenerative disease of the nervous system. The researchers used a neuropathy impairment score to track the progress of the disease. “In this open-label study with patisiran, we are